Английская Википедия:Fruquintinib

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug

Fruquintinib, sold under the brand name Fruzaqla, is an anti-cancer medication used for the treatment of colorectal cancer.[1] Fruquintinib is a kinase inhibitor.[1]

The most common adverse reactions include hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.[2]

Fruquintinib was approved for medical use in the United States in November 2023.[2][3]

Medical uses

Fruquintinib is indicated for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.[1][2][4][5]

History

Efficacy was evaluated in FRESCO-2 (NCT04322539) and FRESCO (NCT02314819).[2] FRESCO-2 (NCT04322539), an international, multicenter, randomized, double-blind, placebo-controlled trial, evaluated 691 participants with metastatic colorectal cancer who had disease progression during or after prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, an anti-VEGF biological therapy an anti-EGFR biological therapy if RAS wild type, and at least one of trifluridine/tipiracil or regorafenib.[2] FRESCO, a multicenter, placebo-controlled trial conducted in China, evaluated 416 participants with metastatic colorectal cancer who had disease progression during or after prior fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy.[2]

References

Шаблон:Reflist

External links

Шаблон:Targeted cancer therapeutic agents Шаблон:Growth factor receptor modulators Шаблон:Portal bar Шаблон:Authority control


Шаблон:Pharma-stub

  1. 1,0 1,1 1,2 Ошибка цитирования Неверный тег <ref>; для сносок Fruzaqla FDA label не указан текст
  2. 2,0 2,1 2,2 2,3 2,4 2,5 Шаблон:Cite web Шаблон:PD-notice
  3. Шаблон:Cite press release
  4. Шаблон:Cite journal
  5. Шаблон:Cite journal